Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg vs placebo in obesity with knee osteoarthritis
2020-000204-11Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and knee osteoarthritis (OA) comparing Semaglutide 2.4 mg once-weekly with Placebo once-weekly (2 arms). Primary endpoints: Change in body weight from baseline to week 68 and Change in knee osteoarthritis-related pain from baseline to week 68. Started Nov 2020; status: completed.
02
Drugs
03
Conditions
obesityknee osteoarthritis (OA)
Beyond the preview
Go deeper on 2020-000204-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000204-11.